TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
Kappa Bioscience AS
Closing information (x1000 NOK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
456,071
|
326,172
|
292,105 |
| Financial expenses |
23,254
|
26,128
|
22,245 |
| Earnings before taxes |
169,458
|
112,706
|
67,303 |
| Total assets |
711,705
|
574,295
|
470,980 |
| Current assets |
281,908
|
211,536
|
214,758 |
| Current liabilities |
240,744
|
87,245
|
145,652 |
| Equity capital |
296,174
|
298,715
|
254,083 |
| - share capital |
1,521
|
1,521
|
1,521 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
41.6%
|
52.0%
|
53.9% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
37.2%
|
34.6%
|
23.0% |
| Return on assets (ROA) |
27.1%
|
24.2%
|
19.0% |
| Current ratio |
117.1%
|
242.5%
|
147.4% |
| Return on equity (ROE) |
57.2%
|
37.7%
|
26.5% |
| Change turnover |
129,899
|
34,067
|
60,034 |
| Change turnover % |
40%
|
12%
|
26% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.